Lee YG, et al. - In this population-based epidemiologic study, researchers assessed whether an upfront combination vs single-agent therapy was beneficial for elderly patients with advanced non-small cell lung cancer (NSCLC) in the real world. Patients ≥70 years with advanced NSCLC from 2007 to 2012 were identified in the National Health Insurance Service Database of Korea. To examine the effect of treatment modality on survival, a Cox proportional-hazards regression model and propensity score analysis were used. It was noted that receiving initial combination chemotherapy vs single-agent was linked with improved survival in elderly patients with advanced NSCLC, after excluding those receiving frontline anti-epidermal growth factor receptor (EGFR) targeted agents.